Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2013

Open Access 01-12-2013 | Research article

Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008–2010: lessons and challenges for low-resource settings

Authors: Joseph Fokam, Serge C Billong, Bissek Anne C ZK, Etienne Kembou, Pascal Milenge, Ibile Abessouguie, Armand S Nkwescheu, Zephirin Tsomo, Avelin F Aghokeng, Grace D Ngute, Peter M Ndumbe, Vittorio Colizzi, Jean BN Elat

Published in: BMC Public Health | Issue 1/2013

Login to get access

Abstract

Background

Rapid scale-up of antiretroviral therapy (ART) and limited access to genotyping assays in low-resource settings (LRS) are inevitably accompanied by an increasing risk of HIV drug resistance (HIVDR). The current study aims to evaluate early warning indicators (EWI) as an efficient strategy to limit the development and spread of preventable HIVDR in these settings, in order to sustain the performance of national antiretroviral therapy (ART) rollout programmes.

Methods

Surveys were conducted in 2008, 2009 and 2010 within 10 Cameroonian ART clinics, based on five HIVDR EWIs: (1) Good prescribing practices; (2) Patient lost to follow-up; (3) Patient retention on first line ART; (4) On-time drug pick-up; (5) Continuous drug supply. Analysis was performed as per the World Health Organisation (WHO) protocol.

Results

An overall decreasing performance of the national ART programme was observed from 2008 to 2010: EWI1 (100% to 70%); EWI2 (40% to 20%); EWI3 (70% to 0%); EWI4 (0% throughout); EWI5 (90% to 40%). Thus, prescribing practices (EWI1) were in conformity with national guidelines, while patient adherence (EWI2, EWI3, and EWI4) and drug supply (EWI5) were lower overtime; with a heavy workload (median ratio ≈1/64 staff/patients) and community disengagement observed all over the study sites.

Conclusions

In order to limit risks of HIVDR emergence in poor settings like Cameroon, continuous drug supply, community empowerment to support adherence, and probably a reduction in workload by task shifting, are the potential urgent measures to be undertaken. Such evidence-based interventions, rapidly generated and less costly, would be relevant in limiting the spread of preventable HIVDR and in sustaining the performance of ART programmes in LRS.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Institut National de la Statistique (INS), République du Cameroun: Enquête Démographique de Santé (EDS IV). 2011, Yaounde: Rapport
4.
HIV Drug Resistance Working Group: Activités de Prévention et de Surveillance des Résistances du VIH aux Médicaments Antirétroviraux au Cameroun. 2010, Yaoundé: National AIDS Control Committee; Rapport Annuel
5.
6.
7.
Gallant JE: Antiretroviral drug resistance and resistance testing. Top HIV Med. 2005–2006, 13 (5): 138-142.
8.
Fokam J, Salpini R, Santoro MM, Cento V, D'Arrigo R, Gori C, Perno CF, Colizzi V, Nanfack A, Gwom LC, Cappelli G, Takou D: Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. Arch Virol. 2011, 156 (7): 1235-1243. 10.1007/s00705-011-0982-3.CrossRefPubMed
9.
Yang C, McNulty A, Diallo K, Zhang J, Titanji B, Kassim S, Wadonda-Kabondo N, Aberle-Grasse J, Kibuka T, Ndumbe PM, Vedapuri S, Zhou Z, Chilima B, Nkengasong JN: Development and Application of a Broadly Sensitive Dried-Blood-Spot-Based Genotyping Assay for Global Surveillance of HIV-1 Drug Resistance. J Clin Microbiol. 2010, 48 (9): 3158-3164. 10.1128/JCM.00564-10.CrossRefPubMedPubMedCentral
10.
Bennett DE, Bertagnolio S, Sutherland D, Gilks CF: The World Health Organization’s global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008, 13 (Suppl 2): 1-13.PubMed
11.
Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D: World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther. 2008, 13 (Suppl 2): 15-23.PubMed
12.
HIV Drug Resistance Working Group: Guidelines for the evaluation of Early Warning Indicators for HIV drug resistance (EWI). 2010, Yaounde: National AIDS control committee
13.
Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF: Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008, 13 (Suppl 2): 25-36.PubMed
14.
Bennett DE: The requirement for surveillance of HIV drug resistance within antiretroviral roll out in the developing world. Curr Opin Infect Dis. 2006, 19 (6): 607-614. 10.1097/QCO.0b013e3280109ff1.CrossRefPubMed
15.
16.
17.
Jordan MR, Bennett DE, Wainberg MA, Havlir D, Hammer S, Yang C, Morris L, Peeters M, Wensing AM, Parkin N, Nachega JB, Phillips A, De Luca A, Geng E, Calmy A, Raizes E, Sandstrom P, Archibald CP, Perriëns J, McClure CM, Hong SY, McMahon JH, Dedes N, Sutherland D, Bertagnolio S: Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004–2011. Clin Infect Dis. 2012 May, 54 (Suppl 4): S245-S249. 10.1093/cid/cis206.CrossRefPubMedPubMedCentral
18.
Hedt BL, Wadonda-Kabondo N, Makombe S, Harries AD, Schouten EJ, Limbambala E, Hochgesang M, Aberle-Grosse J, Kamoto K: Early warning indicators for HIV drug resistance in Malawi. Antivir Ther. 2008, 13 (Suppl 2): 69-75.PubMed
19.
Hong SY, Jonas A, Dumeni E, Badi A, Badi A, Pereko D, Blom A, Muthiani VS, Shiningavamwe AN, Mukamba J, Andemichael G, Barbara R, Bennett DE, Jordan MR: Population-Based Monitoring of HIV Drug Resistance in Namibia with Early Warning Indicators. J Acquir Immune Defic Syndr. 2010, 55 (4): 27-31. 10.1097/QAI.0b013e3181f5376d.CrossRefPubMedPubMedCentral
20.
Dzangare J, Gonese E, Mugurungi O, Shamu T, Apollo T, Bennett DE, Kelley KF, Jordan MR, Chakanyuka C, Cham F, Banda RM: Monitoring of early warning indicators for HIV drug resistance in antiretroviral therapy clinics in Zimbabwe. Clin Infect Dis. 2012, 54 (Suppl 4): S313-S316. 10.1093/cid/cir1014.CrossRefPubMedPubMedCentral
21.
El-Khatib Z, Katzenstein D, Marrone G, Laher F, Mohapi L, Petzold M, Morris L, Ekström AM: Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa. PLoS One. 2011, 6 (3): e17518-10.1371/journal.pone.0017518.CrossRefPubMedPubMedCentral
22.
Sigaloff KC, Hamers RL, Menke J, Labib M, Siwale M, Ive P, Botes ME, Kityo C, Mandaliya K, Wellington M, Osibogun A, Geskus RB, Stevens WS, van Vugt M: Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance: Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. Clin Infect Dis. 2012, 54 (Suppl 4): S294-S299. 10.1093/cid/cir1015.CrossRefPubMed
23.
Bennett DE, Jordan MR, Bertagnolio S, Hong SY, Ravasi G, McMahon JH, Saadani A, Kelley KF: HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis. 2012, 54 (Suppl 4): S280-S289. 10.1093/cid/cis207.CrossRefPubMedPubMedCentral
24.
Jordan M, Kelley K, Hassani SA, Obeng-Aduasare Y, Bertagnolio S: Monitoring ART: Clinic and Program Performance Using WHO HIV Drug Resistance Early Warning Indicators in 21 Countries. 18th CROI. 2011, Boston: Paper # 626, Feb 27 – March 02
25.
Ravasi G, Pérez-Rosales MD, Mejía CVM, Zepeda K, Pérez ME, Aguilar R, Ramos K, Sued O, Alonso Gonzalez M, Israel K: WHO HIV drug resistance early warning indicators as treatment program monitoring and evaluation tool in Central American countries. IAS 2011. 2011, Rome: TUAD 0105
26.
Noreen J, Ravasi G, Schrooten W, Sutherland D, Edwards P, Del Riego A: HIV Drug Resistance Early Warning Indicators in the Caribbean. Caribbean HIV Conference. 2011, The Bahamas: Bahamas
27.
Ma Y, Zhang F, Li H, Wu H, Zhang J, Ding Y, Zhao D, Fang H, Zhou S, Liu Z, Zhang L, Osborne C, Seguy N, Zhao Y: Monitoring HIV drug resistance using early warning indicators in China: results from a pilot survey conducted in 2008. Clin Infect Dis. 2012, 54 (Suppl 4): S300-S302. 10.1093/cid/cir1018.CrossRefPubMed
28.
Daoni E, Kitur U, Parunga A, Ndenzako F, Lloyd A, Yu D: Experience in piloting HIV drug resistance early warning indicators to improve the antiretroviral program in Papua New Guinea. Clin Infect Dis. 2012, 54 (Suppl 4): S303-S305. 10.1093/cid/cir994.CrossRefPubMed
29.
Do TN, Nguyen TM, Do MH, Masaya K, Dang TB, Pham TL, Yoshikawa K, Cao TT, Nguyen TT, Bui DD, Nguyen VK, Nguyen TL, Fujita M: Combining cohort analysis and monitoring of HIV early-warning indicators of drug resistance to assess antiretroviral therapy services in Vietnam. Clin Infect Dis. 2012, 54 (Suppl 4): S306-S312. 10.1093/cid/cir1045.CrossRefPubMed
30.
Jack N, Ravasi G, Schrooten W, Sutherland D, Ghidinelli M, Del Riego A: Implementing early-warning indicators of HIV drug resistance in the Caribbean. Clin Infect Dis. 2012, 54 (Suppl 4): S290-S293. 10.1093/cid/cir1044.CrossRefPubMed
31.
Ravasi G, Jack N, Alonso Gonzalez M, Sued O, Pérez-Rosales MD, Gomez B, Vila M, Riego A, Ghidinelli M: Progress of implementation of the World Health Organization strategy for HIV drug resistance control in Latin America and the Caribbean. Rev Panam Salud Publica. 2011, 30 (6): 657-662. 10.1590/S1020-49892011001200026.CrossRefPubMed
32.
Hirschhorn LR, Oguda L, Fullem A, Dreesch N, Wilson P: Estimating health workforce needs for antiretroviral therapy in resource-limited settings. Hum Resour Health. 2006, 4: 1-10.1186/1478-4491-4-1.CrossRefPubMedPubMedCentral
33.
Atanga NP, Bin KL, Malfertheiner P, Christoph JA: My Friend with HIV Remains a Friend”: A Novel HIV/AIDS Stigma Reduction Project in Cameroon. 2011, Addis Ababa: ICASA, WEPDD 0303
34.
Monge S, Jarrin I, Perez-Hoyos S, Ferreros I, García-Olalla P, Muga R, Del Romero J, Belda J, Castilla J, Bolúmar F, Del Amo J, GEMES: Educational level and HIV disease progression before and after the introduction of HAART. A cohort study in 989 HIV seroconverters in Spain. Sex Transm Infect. 2011, 87 (7): 571-576. 10.1136/sextrans-2011-050125.CrossRefPubMed
35.
Cooke GS, Tanser FC, Bärnighausen TW, Newell ML: Population uptake of antiretroviral treatment through primary care in rural South Africa. BMC Public Health. 2010, 10: 585-10.1186/1471-2458-10-585.CrossRefPubMedPubMedCentral
36.
Comité Nationale de Lutte contre le SIDA au Cameroun: Accès universel pour la PTME, la prise en charge globale des PVVIH et la prévention du VIH auprès des populations les plus exposées au Cameroun. Proposition VIH du Cameroun‐Série 10 (Global Fund Round 10).
37.
Torimiro JN, Takou D, Salpini R, Nanfack A, Fokam J, Cappelli G, Perno CF, Colizzi V: Population Level Drug Resistance Mutations in HIV Type 1 Protease and Reverse Transcriptase in Cameroon: 1995 to 2010 Review. J Acquir Immune Defic Syndr. 2011, 56: 83-CrossRef
38.
Aghokeng AF, Kouanfack C, Laurent C, Ebong E, Atem-Tambe A, Butel C, Montavon C, Mpoudi-Ngole E, Delaporte E, Peeters M: Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS. 2011, 25 (17): 2183-2188. 10.1097/QAD.0b013e32834bbbe9.CrossRefPubMed
39.
Boyer S, Eboko F, Camara M, Abé C, Nguini ME, Koulla-Shiro S, Moatti JP: Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon. AIDS. 2010, 24 (Suppl 1): S5-S15. 10.1097/01.aids.0000366078.45451.46.CrossRefPubMed
40.
Aghokeng FA, Vergne L, Mpoudi NE, Mbangue M, Deoudje N, Mokondji E, Nambei WS, Peyou-Ndi MM, Moka JJ, Delaporte E, Peeters M: Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther. 2009, 14 (3): 401-411.PubMed
41.
Kouanfack C, Montavon C, Laurent C, Aghokeng A, Kenfack A, Bourgeois A, Koulla-Shiro S, Mpoudi-Ngole E, Peeters M, Delaporte E: Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis. 2009, 48 (9): 1318-1322. 10.1086/597779.CrossRefPubMed
42.
World Health Organization: Antiretroviral Therapy for HIV infection in children and infants: Toward Universal Access. Recommendations for public health approach. World Health Organization 2010 revision. 2010, Geneva: World Health Organization, 83-86. Available at: http://​www.​who.​int/​hiv/​pub/​guidelines/​art/​en. Accessed 2011 Apr 10
43.
Fokam J, Salpini R, Santoro MM, Cento V, Perno CF, Colizzi V, Ndumbe PM, Fokunang Ntungen C, Ndiang Tetang SM, Nanfack AJ, Takou Komego DA, Cappelli G: Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon. Pediatr Infect Dis J. 2011, 30 (12): 1062-1068. 10.1097/INF.0b013e31822db54c.CrossRefPubMed
44.
Hedt BL, Laufer MK, Cohen T: Drug resistance surveillance in resource-poor settings: current methods and considerations for TB, HIV, and malaria. Am J Trop Med Hyg. 2011, 84 (2): 192-199. 10.4269/ajtmh.2011.10-0363.CrossRefPubMedPubMedCentral
45.
Metadata
Title
Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008–2010: lessons and challenges for low-resource settings
Authors
Joseph Fokam
Serge C Billong
Bissek Anne C ZK
Etienne Kembou
Pascal Milenge
Ibile Abessouguie
Armand S Nkwescheu
Zephirin Tsomo
Avelin F Aghokeng
Grace D Ngute
Peter M Ndumbe
Vittorio Colizzi
Jean BN Elat
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2013
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-13-308

Other articles of this Issue 1/2013

BMC Public Health 1/2013 Go to the issue

Research article

Examining the cost effectiveness of interventions to promote the physical health of people with mental health problems: a systematic review

Research article

Smoke-free or not: a pilot evaluation in selected Beijing Hospitals

Research article

Cyclical iron supplementation to reduce anemia among Brazilian preschoolers: a randomized controlled trial

Research article

Impact of duration of structured observations on measurement of handwashing behavior at critical times

Research article

Health-related quality of life and long-term care needs among elderly individuals living alone: a cross-sectional study in rural areas of Shaanxi Province, China

Research article

Testing the association between social capital and health over time: a family-based design